Yohei Yamamoto, Toshihide Tanaka, Akihiko Teshigawara, Takuya Ishii, Yasuharu Akasaki, Yuichi Murayama. 10031- MET-5 CHANGES IN PROGNOSTIC FACTORS IN PATIENTS WITH BRAIN METASTASES FROM LUNG CANCER. Neuro-Oncology Advances. 2024. 6. Supplement_4. iv20-iv21
Yohei Yamamoto, Kyoichi Tomoto, Akihiko Teshigawara, Takuya Ishii, Yuzuru Hasegawa, Yasuharu Akasaki, Yuichi Murayama, Toshihide Tanaka. Significance and priority of surgical resection as therapeutic strategy based on clinical characteristics of brain metastases from renal cell carcinoma. World Neurosurgery. 2024
Taketo Ezaki, Toshihide Tanaka, Ryota Tamura, Kentaro Ohara, Yohei Yamamoto, Jun Takei, Yukina Morimoto, Ryotaro Imai, Yuki Kuranai, Yasuharu Akasaki, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathology. 2024. 41. 2. 61-72
Ai Iwauchi, Nei Fukasawa, Jun Takei, Miku Maeda, Kyoichi Tomoto, Akihiko Teshigawara, Yohei Yamamoto, Yasuharu Akasaki, Yuzuru Hasegawa, Yuichi Murayama, et al. Comparative analyses of erythroblast transformation specific-1 related gene expression before and after neoadjuvant bevacizumab therapy for newly diagnosed glioblastoma. International journal of clinical and experimental pathology. 2024. 17. 10. 346-359
Toshihide Tanaka, Ryota Tamura, Jun Takei, Yukina Morimoto, Akihiko Teshigawara, Kyoichi Tohmoto, Yuki Kuranari, Ryotaro Imai, Yohei Yamamoto, Yuzuru Hasegawa, et al. 10001-ACT-1 A MULTICENTER EXPLORATORY PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED MALIGNANT GLIOMA - THE SECOND REPORT. Neuro-Oncology Advances. 2023. 5. Supplement_5. v1-v1
MET-2 Clinical features of renal cell carcinoma brain metastases compared with other carcinomas. 2023. 5. 5. v4-v4
Akasaki Y, Kikuchi T, Tanaka T, Murayama Y. Dendritic cell immunotherapy for malignant glioma: Research history for 25 years and the future perspectives. Neuro-Oncology Advances. 2022. 4. 3. iii27
Akasaki Y, Suzuki T, Takei J, Tanaka T, Mori R, Koseki H, Yamamoto Y, Teshigawara A, Kamata Y, Yanagisawa T, et al. Pros and cons of surgical intervention for diffuse midline glioma aimed at dendritic cell immunotherapy. Neuro-Oncology Advances. 2022. 4. 3. iii12
Yamamoto Y, Nawate S, Nakamura A, Ishii T, Tanaka T, Akasaki Y, Murayama Y. Analysis of metastatic brain tumors discovered at the same time as the primary lesion. Neuro-Oncology Advances. 2022. 4. 3. iii21-iii22
Tohmoto K, Yamamoto Y, Tanaka T, Suzuki T, Teshigawara A, Takei J, Koseki H, Mori R, Akasaki Y, Murayama Y. Clinical benefit of add-on bevacizumab for newly diagnosed glioblastoma in elderly patients with unresectable and poor performance status. Neuro-Oncology Advances. 2022. 4. 3. iii8
